Owkin, headquartered in France, remains privately held in the biotech / ai space. Its shares do not trade on a public exchange.
1 valuation. The latest, $1B post-money, was set by the Strategic investment in Nov 2021.
GVNNJF CapitalCCathay InnovationFF-PrimeEEight Roads VenturesOwkin builds agentic AI systems for biomedical research, combining biological large language models with multimodal patient data to help pharmaceutical companies identify treatments, de-risk clinical development, and connect research to patient care. Founded in 2016 and headquartered in France, the company's flagship product, K Pro, launched in October 2025 as what it calls the first agentic AI co-pilot for biopharma.
In September 2026 Owkin licensed K Pro and its multimodal data to Servier to advance oncology research, extending a customer base built around pharmaceutical and biotech drug discovery.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Owkin.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Owkin availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Owkin included.
The closest biotech / ai peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Owkin is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
